Table 4.

Sensitivity analysis: associations of vascular risk burden and neuropathology outcomes using inverse probability weighting.

Outcome	Mid‐life vascular risk Model 1		Mid‐life vascular risk Model 2		Late‐life vascular risk Model 3
	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Cerebrovascular pathology
Cortical infarcts	1.96 (0.67, 5.74)	0.100	1.92 (0.67, 5.51)	0.228	1.03 (0.99, 1.07)	0.115
Subcortical infarcts	1.63 (0.90, 2.94)	0.142	1.59 (0.89, 2.83)	0.115	1.02 (0.99, 1.05)	0.210
Atherosclerosis	1.79 (1.11, 2.87)	0.017*	1.80 (1.11, 2.93)	0.019*	1.03 (1.00, 1.06)	0.045*
Arteriosclerosis	1.83 (0.94, 3.55)	0.074	1.90 (0.95, 3.83)	0.071	1.02 (0.99, 1.05)	0.224
Proteinopathy
Braak NFT stage	0.82 (0.48, 1.40)	0.466	0.85 (0.48, 1.48)	0.562	1.02 (0.99, 1.05)	0.206
Cerebral amyloid angiopathy	0.95 (0.59, 1.55)	0.852	1.01 (0.60, 1.70)	0.974	1.01 (0.98, 1.05)	0.412
CERAD neuritic plaque score	0.62 (0.36, 1.08)	0.090	0.64 (0.36, 1.13)	0.126	1.01 (0.98, 1.04)	0.600

OR, Odds ratio, CI, confidence interval; P: P‐value; CERAD, Consortium to Establish a Registry for Alzheimer's Disease.

Model 1: Adjusted for presence of ApoE ɛ4 and elapsed time between mid‐life vascular risk and death (with quadratic term for atherosclerosis and arteriosclerosis).

Model 2: Model 1 additionally adjusted for late‐life vascular risk.

Model 3: Adjusted for presence of ApoE ɛ4, and elapsed time between late‐life vascular risk and death.

^* P < 0.05.